For the report, entitled “Global Pharmaceutical R&D Pipeline,” analysts examined novel drug applications approved by the FDA’s Center for Drug Evaluation and Research in 2017 and the first four months of 2018.
Here are three report findings:
1. The agency signed off on 10 new medications in the first four months of 2018, compared to 18 new drug products over the same time period in 2017.
2. Biologic approvals accounted for 30 percent of approvals in 2018, up from 29 percent in 2017.
3. The agency pushed through eight priority review new drug approvals so far this year, compared to nine during the same period last year.
More articles on supply chain:
3 ways FDA seeks to modernize its drug approval office
Hospira recalls opioid overdose antidote
FDA confirms 5 more patient deaths linked to balloon obesity devices: 5 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
